European Journal of Clinical Pharmacology

, Volume 75, Issue 2, pp 217–226 | Cite as

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

  • Matthew P. Kosloski
  • Haoyu Wang
  • David Pugatch
  • Federico J. Mensa
  • Edward Gane
  • Eric Lawitz
  • Thomas C. Marbury
  • Richard A. Preston
  • Jens Kort
  • Wei LiuEmail author
Pharmacokinetics and Disposition



This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection.


HCV-negative subjects with normal hepatic function, or with mild (Child-Pugh [CP]-A), moderate (CP-B), or severe (CP-C) hepatic impairment received single doses of pibrentasvir 120 mg alone or with glecaprevir 200 mg or 300 mg (n = 6/functional group/dose). Plasma pharmacokinetics and protein binding were evaluated. Doses were separated by ≥ 14 days of washout.


For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was ≤ 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C). For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (≤ 12% difference). Pibrentasvir 120 mg alone AUC increased 51% (CP-A), 31% (CP-B), and to 5.2-fold (CP-C). The unbound fraction of glecaprevir was higher in CP-C subjects than normal subjects and pibrentasvir protein binding was similar across groups. The most common adverse event was headache; no events were serious.


This study supported evaluation of the glecaprevir 300 mg with pibrentasvir 120-mg combination in HCV-infected subjects with CP-A hepatic impairment without dose adjustment. Elevated glecaprevir and/or pibrentasvir exposures are expected in HCV-infected patients with CP-B or CP-C hepatic impairment.


Glecaprevir Pibrentasvir Pharmacokinetics Hepatitis C virus Hepatic impairment 



The authors thank AbbVie employee Sonja Causemaker for medical writing support of this manuscript.

Authors’ contributions

MPK, HW, DP, FJM, EG, EL, TCM, RAP, JK, and WL contributed to the study design and analysis and interpretation of the data as well as the drafting and revising of the manuscript.


This study was funded by AbbVie. AbbVie participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review, and approval of the manuscript.

Compliance with ethical standards

Conflict of interest

Matthew Kosloski, Haoyu Wang, David Pugatch, Federico Mensa, Jens Kort, and Wei Liu are employees of AbbVie, Inc. and may hold stock or stock options. Edward Gane is faculty at University of Auckland, Auckland, New Zealand, is a consultant/Advisory Board member for AbbVie, Gilead, Janssen, and Merck/MSD, and is a speaker for AbbVie and Gilead. Eric Lawitz is an employee of Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA and is a speaker for AbbVie, Gilead, and Merck. Dr. Lawitz has received research/grant support from AbbVie, Boehringer Ingelheim, BMS, Gilead Sciences, GSK, Intercept Pharmaceuticals, Janssen, Merck, and Novartis, and he serves as an advisor for AbbVie, Achillion, BioCryst, Biotica, Enanta, Janssen, Merck, and Novartis. Thomas C. Marbury is an employee and equity owner of Orlando Clinical Research Center, Orlando, FL, USA and has no other conflicts of interest to disclose. Richard A. Preston is faculty at the Miller School of Medicine, University of Miami, Miami, FL, USA and he has received grant/research support from AbbVie, Celerion, Chiasma, Celgene, Conatus, Forest, Pfizer, Parexel, PPD, Takeda, Novartis, Exelixis, Idenix, PPD, Akros, ApoPharma, Merck, Fujifi lm, Reata, and Watson.

Ethical approval

The study was conducted in accordance with International Conference for Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from each subject before any study-related procedures were performed.

Supplementary material

228_2018_2576_MOESM1_ESM.docx (17 kb)
ESM 1 (DOCX 17 kb)


  1. 1.
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538CrossRefGoogle Scholar
  2. 2.
    Lu M, Gordon SC, Li J, Rupp LB, Zhou Y, Moorman AC et al (2016) Hepatitis C complications: prevalence and disparities in a large US cohort 2006–2014. Hepatology 64. Plenary and Parallel Sessions (Abstract 180)Google Scholar
  3. 3.
    AASLD-IDSA (2017) HCV guidance: recommendations for testing, managing, and treating hepatitis. Available from:
  4. 4.
  5. 5.
    AbbVie (2017) Maviret (glecaprevir and pibrentasvir tablets) . Summary of product characteristics. Maidenhead, United KingdomGoogle Scholar
  6. 6.
    AbbVie (2017) MAVYRET (glecaprevir and pibrentasivr tablets) [US package insert]. North Chicago, IL, USAGoogle Scholar
  7. 7.
    Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ (2017) Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17:1062–1068CrossRefGoogle Scholar
  8. 8.
    Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ (2018) Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 67:514–423CrossRefGoogle Scholar
  9. 9.
    Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ (2018) High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol 69:293–300. CrossRefGoogle Scholar
  10. 10.
    Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ (2018) Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378:354–369CrossRefGoogle Scholar
  11. 11.
    Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633–646CrossRefGoogle Scholar
  12. 12.
    Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38:717–727CrossRefGoogle Scholar
  13. 13.
    Micuda S, Brcakova E, Fuksa L, Cermanova J, Osterreicher J, Hroch M, Mokry J, Pejchal J, Martinkova J, Staud F (2008) P-glycoprotein function and expression during obstructive cholestasis in rats. Eur J Gastroenterol Hepatol 20:404–412CrossRefGoogle Scholar
  14. 14.
    Yumoto R, Murakami T, Takano M (2003) Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. Pharm Res 20:765–771CrossRefGoogle Scholar
  15. 15.
    Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, Inui KI (2010) Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 25:190–199CrossRefGoogle Scholar
  16. 16.
    World Health Organization Hepatitis C Fact Sheet. [online] [viewed on 19/10/2017] Available at: 2017;JulyGoogle Scholar
  17. 17.
    Lin CW, Dutta S, Asatryan A, Chiu YL, Wang H, Clifton J, 2nd et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study. J Pharm Sci 2017;106:645–651Google Scholar
  18. 18.
    Lin C-W, Dutta S, Asatryan A, Wang H, Clifton J, Campbell A et al (2017) Pharmacokinetics and tolerability following single and multiple doses of ABT-530 in a first-in-human study. Clin Pharmacol Drug Dev 00:1–9Google Scholar
  19. 19.
    Kosloski MP, Dutta S, Wang H, Pugatch D, Mensa F, Kort J et al (2016) Pharmacokinetics, safety, and tolerability of next generation direct acting antivirals ABT-493 and ABT-530 in subjects with hepatic impairment. European Association for the Study of the Liver (EASL); 13–17 April, Barcelona, Spain. Available from:
  20. 20.
    Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W (2018) Pharmacokinetic interactions and safety of Coadministration of Glecaprevir and Pibrentasvir in healthy volunteers. Eur J Drug Metab Pharmacokinet 43:81–90CrossRefGoogle Scholar
  21. 21.
    U.S. Department of Health and Human Services (DHHS), Food and Drug Administration (FDA) (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, And impact on dosing and labelingGoogle Scholar
  22. 22.
    Child CG, Turcotte JG (1964) Surgery and portal hypertension. Major Probl Clin Surg 1:1–85Google Scholar
  23. 23.
    Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH (1997) Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 3:628–637CrossRefGoogle Scholar
  24. 24.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRefGoogle Scholar
  25. 25.
    Kalvass JC, Phipps C, Jenkins GJ, Stuart P, Zhang X, Heinle L, Nijsen MJMA, Fischer V (2018) Mathematical and experimental validation of flux Dialysis method: an improved approach to measure unbound fraction for compounds with high protein binding and other challenging properties. Drug Metab Dispos 46:458–469CrossRefGoogle Scholar
  26. 26.
    Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653CrossRefGoogle Scholar
  27. 27.
    Patilea-Vrana G, Unadkat JD (2016) Transport vs. metabolism: what determines the pharmacokinetics and pharmacodynamics of drugs? Insights from the extended clearance model. Clin Pharmacol Ther 100:413–418CrossRefGoogle Scholar
  28. 28.
    Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, Ganten TM, Sauer P, Haefeli WE (2014) CYP3A activity in severe liver cirrhosis correlates with child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 77:160–169CrossRefGoogle Scholar
  29. 29.
    More VR, Cheng Q, Donepudi AC, Buckley DB, Lu ZJ, Cherrington NJ, Slitt AL (2013) Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos 41:1148–1155CrossRefGoogle Scholar
  30. 30.
    Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CECA, Kumer SC, Unadkat JD (2016) Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab Dispos 44:1752–1758CrossRefGoogle Scholar
  31. 31.
    Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161CrossRefGoogle Scholar
  32. 32.
    Merck (2018) Zepatier™ (elbasvir and grazoprevir) [US package insert]. Merck & Co., Inc, Whitehouse Station, NJGoogle Scholar
  33. 33.
    AbbVie (2017) Viekira XR (dasabuvir, ombitasvir, paritaprevir, ritonavir) [US package insert]. AbbVie Inc., North ChicagoGoogle Scholar
  34. 34.
    Khatri A, Menon RM, Marbury TC, Lawitz EJ, Podsadecki TJ, Mullally VM, Ding B, Awni WM, Bernstein BM, Dutta S (2015) Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 63:805–812CrossRefGoogle Scholar
  35. 35.
    European Medicines Agency (EMA), Evaluation of Medicines for Human Use, Committee for Medicinal Products for human use (CHMP) (2005) Guideline on the evaluation of pharmacokinetics of medicinal products in patients with impaired hepatic functionGoogle Scholar
  36. 36.
    Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ (2017) Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 67:263–271CrossRefGoogle Scholar
  37. 37.
    Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ (2017) Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66:389–397CrossRefGoogle Scholar
  38. 38.
    Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ (2016) High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 151:651–659CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Matthew P. Kosloski
    • 1
  • Haoyu Wang
    • 2
  • David Pugatch
    • 3
  • Federico J. Mensa
    • 3
  • Edward Gane
    • 4
  • Eric Lawitz
    • 5
  • Thomas C. Marbury
    • 6
  • Richard A. Preston
    • 7
    • 8
  • Jens Kort
    • 9
  • Wei Liu
    • 1
    Email author
  1. 1.Clinical Pharmacology and Pharmacometrics, AbbVie Inc.North ChicagoUSA
  2. 2.Data and Statistical Sciences, AbbVie Inc.North ChicagoUSA
  3. 3.Infectious Diseases, AbbVie Inc.North ChicagoUSA
  4. 4.University of AucklandAucklandNew Zealand
  5. 5.Texas Liver InstituteUniversity of Texas HealthSan AntonioUSA
  6. 6.Orlando Clinical Research CenterOrlandoUSA
  7. 7.Division of Clinical Pharmacology, Department of Medicine, Miller School of MedicineUniversity of MiamiMiamiUSA
  8. 8.Department of Cellular Biology and Pharmacology, Herbert Wertheim College of MedicineFlorida International UniversityMiamiUSA
  9. 9.Medical Affairs, AbbVie Inc.North ChicagoUSA

Personalised recommendations